Clinical Trial Results:
Phase 3, Multi-center, double-blind, randomized, parallel group study of the efficacy, safety, and tolerability of fixed combination torcetrapib (CP-529,414)/Atorvastatin administered orally, once daily (QD) for six months, compared with maximally tolerated Atorvastatin therapy alone, in subjects with heterozygous familial hypercholesterolemia.
Summary
|
|
EudraCT number |
2004-004269-14 |
Trial protocol |
SE DK IS |
Global completion date |
03 Mar 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Aug 2016
|
First version publication date |
24 Aug 2016
|
Other versions |
|
Summary report(s) |
A5091026_Public Disclosure Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.